John Moore

List of Publications by Citations

Source: https://exaly.com/author-pdf/8754249/john-moore-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49
papers

1,926
citations

19
h-index

52
ext. papers

2,252
ext. citations

5.2
ext. citations

3.76
L-index

#	Paper	IF	Citations
49	Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 yearsTexperience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. <i>Haematologica</i> , 2010 , 95, 284-92	6.6	267
48	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). <i>Blood</i> , 2012 , 120, 1570-80; quiz 1752	2.2	213
47	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncology, The</i> , 2016 , 17, 164-17	21.7 3	199
46	Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. <i>Lancet Infectious Diseases, The</i> , 2013 , 13, 519-28	25.5	180
45	A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2301-9		140
44	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. <i>Blood Advances</i> , 2017 , 1, 2742-2755	7.8	114
43	Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. <i>Lancet Haematology,the</i> , 2015 , 2, e357-66	14.6	89
42	Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. <i>Arthritis and Rheumatism</i> , 2007 , 56, 753-64		81
41	Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 601-7	4.7	70
40	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation	4.4	61
39	Committee of EBMT and ISCT (JACIE). <i>Bone Marrow Transplantation</i> , 2020 , 55, 283-306 Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Research, 2005 , 7, R80-92		58
38	Endothelial progenitor cells, angioblasts, and angiogenesisold terms reconsidered from a current perspective. <i>Trends in Cardiovascular Medicine</i> , 2008 , 18, 45-51	6.9	56
37	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre,	14.6	32
36	A survey of fertility and sexual health following allogeneic haematopoietic stem cell transplantation in New South Wales, Australia. <i>British Journal of Haematology</i> , 2016 , 172, 592-601	4.5	32
35	IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. <i>Cytokine</i> , 2010 , 50, 58-	6 8	30
34	Safety and efficacy of consecutive cycles of granulocyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: the G-CSF in angina patients with IHD to stimulate neovascularization (GAIN I) trial. <i>American Heart</i>	4.9	26
33	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and	4.4	22

(2015-2006)

32	A SYBR green-based real-time PCR method for detection of haemopoietic chimerism in allogeneic haemopoietic stem cell transplant recipients. <i>European Journal of Haematology</i> , 2006 , 77, 425-31	3.8	20
31	Detection of drug effects on gastric emptying and contractility using a wireless motility capsule. <i>BMC Gastroenterology</i> , 2014 , 14, 2	3	19
30	Profound thrombocytopenia related to G-CSF. American Journal of Hematology, 2007, 82, 229-30	7.1	19
29	What They Want: Inclusion of Blood and Marrow Transplantation Survivor Preference in the Development of Models of Care for Long-Term Health in Sydney, Australia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 731-743	4.7	17
28	Haematopoietic stem cell transplantation survivorship and quality of life: is it a small world after all?. <i>Supportive Care in Cancer</i> , 2017 , 25, 421-427	3.9	16
27	Stem cells in the aetiopathogenesis and therapy of rheumatic disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001 , 15, 711-26	5.3	16
26	General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor	4.4	15
25	Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Granulocyte colony stimulating factor in chronic angina to stimulate neovascularisation: a placebo controlled crossover trial. Heart, 2012, 98, 282-90	5.1	15
24	Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT). <i>Cancer Medicine</i> , 2016 , 5, 1702-16	4.8	13
23	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017 , 35, 1678-1685	2.2	12
22	Autologous hematopoietic stem cell transplant for systemic sclerosis improves anemia from gastric antral vascular ectasia. <i>Journal of Rheumatology</i> , 2015 , 42, 554-5	4.1	10
21	A survey of infectious diseases and vaccination uptake in long-term hematopoietic stem cell transplant survivors in Australia. <i>Transplant Infectious Disease</i> , 2019 , 21, e13043	2.7	10
20	A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. <i>British Journal of Haematology</i> , 2012 , 157, 766-9	4.5	8
19	Nutritional issues and body weight in long-term survivors of allogeneic blood and marrow transplant (BMT) in NSW Australia. <i>Supportive Care in Cancer</i> , 2017 , 25, 137-144	3.9	7
18	Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. <i>Internal Medicine Journal</i> , 2018 , 48, 276-285	1.6	7
17	Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation. <i>Reviews on Recent Clinical Trials</i> , 2008 , 3, 130-8	1.2	7
16	Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia. <i>Cancer Medicine</i> , 2016 , 5, 3606-3614	4.8	7
15	Small-molecule inhibitor of glycogen synthase kinase 3년-Bromoindirubin-3-oxime inhibits hematopoietic regeneration in stem cell recipient mice. <i>Stem Cells and Development</i> , 2015 , 24, 724-36	4.4	6

14	Early and late posttransplant lymphoproliferative disorder after lung transplantation34 cases from the European PTLD Network. <i>Transplantation</i> , 2013 , 96, e18-9	1.8	6
13	Rituximab and its potential for the treatment of rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2006 , 2, 207-12	2.9	6
12	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1868-1875	4.7	4
11	Fear of cancer recurrence following allogeneic haematopoietic stem cell transplantation (HSCT) for haematological malignancy: A cross-sectional study. <i>European Journal of Oncology Nursing</i> , 2020 , 49, 101845	2.8	4
10	Cushingቼ syndrome can precipitate diabetes but mask non-Hodgkinቼ lymphoma. <i>Medical Journal of Australia</i> , 2008 , 188, 262	4	3
9	Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1478-1482	4.4	3
8	Changes to work status and household income of long-term allogeneic blood and marrow transplant survivors in New South Wales, Australia. <i>Bone Marrow Transplantation</i> , 2018 , 53, 926-931	4.4	2
7	Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple Sclerosis <i>Frontiers in Immunology</i> , 2022 , 13, 798300	8.4	2
6	Long-term treatment burden following allogeneic blood and marrow transplantation in NSW, Australia: a cross-sectional survey. <i>Journal of Cancer Survivorship</i> , 2021 , 1	5.1	0
5	Two cases of successful autologous stem cell transplantation in patients with multiple myeloma and concurrent chronic myeloid leukaemia. <i>Bone Marrow Transplantation</i> , 2021 , 56, 514-516	4.4	Ο
4	Predictors of quality of life in allogeneic hematopoietic stem cell transplantation survivors. <i>Journal of Psychosocial Oncology</i> , 2021 , 39, 534-552	2.8	0
3	Stem cell transplantation in rheumatic diseases. APLAR Journal of Rheumatology, 2003, 6, 79-82		
2	Outcomes for Allogeneic Stem Cell Transplantation in Secondary AML Are Inferior to De Novo AML and Are Independent of the Disease Risk Index. <i>Blood</i> , 2021 , 138, 3958-3958	2.2	
1	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation.	4.5	